Immunology and Microbiology
Immunotherapy
83%
CD22
71%
Mouse
69%
Monoclonal Antibody
67%
Immunotoxin
46%
Monospecific Antibody
38%
Tumor Cell
36%
Ricin
31%
Immune Response
29%
Neutrophil Granulocyte
28%
Regulatory T Cell
28%
Immune System
28%
Dormancy
28%
Antineoplastic Activity
26%
Pharmacokinetics
25%
B Cell
22%
Immunocompetent Cell
21%
Cell Line
19%
Vaccine Efficacy
19%
SCID Mouse
18%
Autoantibodies
17%
Fc Receptor
15%
CD19
15%
Syngenic
14%
Rhesus Monkey
14%
Vaccination Policy
14%
Epitope
14%
Intercellular Adhesion Molecule 1
14%
Neoantigen
14%
Drug Megadose
14%
Plasma Half Life
14%
Leukemia Cell Line
14%
Sirolimus
14%
Melanoma Cell
14%
Immunogenicity
14%
interferon
14%
Glucagon Release
14%
Mouse Model
14%
P-Glycoprotein
14%
Clonal Variation
14%
Cytotoxicity
14%
Gene Expression
14%
Granulocyte Colony-Stimulating Factor
14%
Drug-Induced Lupus Erythematosus
14%
Neutrophil Response
14%
Neutralizing Antibody
14%
B-Cell Lymphoma Cell Line
14%
Immune Checkpoint Blockade
14%
Tumor Immunity
14%
Inflammation Response
14%
Medicine and Dentistry
Neoplasm
100%
Radiation Therapy
97%
Clear Cell Renal Cell Carcinoma
45%
Monoclonal Antibody
31%
Drug Megadose
28%
Phase II Trials
28%
Leukemia Cell Line
28%
Acute Lymphoblastic Leukemia
28%
B-Cell Lymphoma
28%
Clinical Trial
22%
Gene Expression Profiling
21%
Immunotherapy
20%
In Vitro
20%
Antineoplastic Activity
19%
Patient with Type 2 Diabetes
18%
SCID Mouse
17%
Kidney Cancer
17%
Treatment Response
17%
Metastatic Carcinoma
16%
Tumor Cell
16%
Adverse Event
14%
Intercellular Adhesion Molecule 1
14%
Diagnosis
14%
Immunotoxin
14%
Interleukin 2
14%
Sulfonylurea
14%
Chemoradiotherapy
14%
Interleukin 8 Receptor, Beta
14%
Cytostatic Agent
14%
Clinical Stage
14%
Placebo
14%
Acute B-Cell Lymphoblastic Leukemia
14%
Sipuleucel T
14%
Chemoimmunotherapy
14%
Precursor
14%
Adaptive Radiotherapy
14%
Melanoma Cell
14%
Uveal Melanoma
14%
Roux-en-Y Gastric Bypass
14%
Bone Density
14%
Cardiovascular System
14%
Interferon Type I
14%
Diabetes
14%
Lipid Metabolism
14%
Pioglitazone
14%
Divalent
14%
Inferior Vena Cava
14%
Prostate Cancer
14%
Liraglutide
14%
Oncology
14%
Keyphrases
Immunotoxin
46%
Monoclonal Antibody
46%
CD22
46%
Radiation Therapy
43%
Stereotactic Ablative Radiotherapy
43%
Phase II Trial
43%
Radiation Effects
39%
Tetravalent
28%
Type 2 Diabetic Patients
28%
Tumor
24%
Recombinant
22%
Mechanism of Action
17%
SCID Mice
17%
Diabetes
15%
Liraglutide
15%
Immune Cells
14%
Renal Cancer
14%
Immune Correlates
14%
Glucagon-like
14%
Immune Parameters
14%
Intercellular Adhesion molecule-1 (ICAM-1)
14%
Favorable Outcome
14%
Systemic Immune Response
14%
Transcriptome Analysis
14%
Anti-CD22 Antibody
14%
Serum Half-life
14%
CXCR2
14%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
14%
Antitumor Effect
14%
Receptor Agonist
14%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
Human B Cells
14%
Pancreatic Ductal Adenocarcinoma
14%
Uveal Melanoma Cells
14%
Asymptomatic Period
14%
Treatment Response Evaluation
14%
Uveal Melanoma
14%
Craiova
14%
International Criteria
14%
Sipuleucel-T
14%
Cauchy-Schwarz
14%
Precursor B-cell Acute Lymphoblastic Leukemia
14%
Human Hepatocellular Carcinoma
14%
High-dose Insulin
14%
Much Ado About Nothing
14%
Vascular Leak
14%
Tumor Immunity
14%
Pancreatic Cancer
14%
Pioglitazone
14%
Diabetic Kidney Disease
14%